Fig. 3From: Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosisEffects of DOX and OKI-005 on downstream effectors of DNA damage, apoptosis, and cell cycle. Cells were treated for 24 h with DOX (0.5 µM), OKI-005 (0.2 µM), or combinationBack to article page